Guillain-Barré syndrome after mRNA-1273 (Moderna) COVID-19 vaccination: A case report

Clin Case Rep. 2022 Apr 14;10(4):e05733. doi: 10.1002/ccr3.5733. eCollection 2022 Apr.


Guillain-Barre syndrome (GBS) is an acquired inflammatory polyradiculoneuropathy that often follows infection with a virus or bacteria and in rare occasions, vaccination may precede GBS. We present a case of 80-year-old male patient who presented with chief complaints of progressive, ascending bilateral lower extremity paresthesia and weakness following first dose of Moderna vaccine. His symptoms got exacerbated after 2nd dose. Clinical examination and investigation findings including lumbar puncture, nerve conduction study, and electromyography were consistent with the diagnosis of GBS. The patient received treatment with intravenous immunoglobulin and there was significant improvement toward the end of 5th day. Though rare, this case report suggest that physician should remain vigilant for GBS following COVID-19 vaccination.

Keywords: COVID‐19; GBS; Moderna; mRNA; vaccine.

Publication types

  • Case Reports